Selank

Selank is a 6.5–7.0/10 fit for people weighing anxiety, mood, and stress resilience, especially when the goal is a tracked experiment with clear endpoints. The strongest evidence anchor is Zozulia 2008: Corrected key human anxiety comparator study; 62 patients, Selank versus medazepam; old v0.x anxiety identifier was unrelated. Medvedev 2014 adds a second signal, but Selank still has gaps around large trials, long-term outcomes, responder profiles, or real-world adherence. That makes Selank useful for a defined reader, while weaker for broad anti-aging or catch-all wellness claims. In practice, Selank belongs after basics, diagnosis when relevant, and a stop rule based on symptoms, labs, sleep, or performance.

✅ Best for: Adults with acute or stress-linked anxiety who want a non-sedating option and understand that Selank is evidence-limited outside Russia. It is most defensible for people who have already handled basics like sleep, caffeine, alcohol, exercise, therapy access, and magnesium or L-theanine-style low-risk supports, and who are willing to run a short, clean, single-variable intranasal trial. Selank is especially relevant when benzodiazepines feel too impairing or dependency-prone, but the user does not need emergency anxiety care.

❌ Avoid if: You require FDA-approved or Western-RCT-backed treatments, are pregnant or breastfeeding, have unstable psychiatric symptoms, are using benzodiazepines or sedatives without clinician oversight, have chronic nasal inflammation that makes dosing unreliable, or compete in drug-tested sport without anti-doping review. Also avoid Selank if it would delay CBT, exposure therapy, SSRI/SNRI discussion, or urgent care. The WADA S0 category and FDA compounding concerns make casual athlete or injectable use a poor default.